Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | ASH 2014: Phase II/III study of lenalidomide in relapsed/refractory diffuse large B-cell lymphoma

Andrew Davies • 6 Dec 2013
ASH 2014
B-Cell Lymphoma Lenalidomide

Dr Andrew Davies (University of Southampton, Southampton, UK) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses a phase II/III study comparing the efficacy and safety of lenalidomide versus investigator’s choice in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Studies continue to support the clinical importance of molecularly distinct subtypes of DLBCL.

More from Andrew Davies

Novel therapies in NHL: antibody-drug conjugates
Novel therapies in NHL: antibody-drug conjugates
Andrew Davies et al. • 17 Oct 2023
Economic burden of CAR-T therapy from a UK perspective
1:11
Economic burden of CAR-T therapy from a UK perspective
Andrew Davies • 24 Apr 2023
Primary analysis of the Phase III TRANSFORM study: liso-cel in second-line LBCL
2:40
Primary analysis of the Phase III TRANSFORM study: liso-cel in second-line LBCL
Andrew Davies • 24 Apr 2023
REMoDL-B: bortezomib + R-CHOP versus R-CHOP in patients with DLBCL
1:44
REMoDL-B: bortezomib + R-CHOP versus R-CHOP in patients with DLBCL
Andrew Davies • 24 Apr 2023

Related Videos

Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Lessons from the US: NCCN guidelines enable early access to novel MCL treatments
1:00
Lessons from the US: NCCN guidelines enable early access to novel MCL treatments
Yucai Wang • 10 Sep 2026
Lessons from the US: treatment access and patient-guided treatment selection in MCL
0:51
Lessons from the US: treatment access and patient-guided treatment selection in MCL
Elise Chong • 10 Sep 2026
BTKi selection in R/R MCL: implications for sequencing non-covalent BTKis
1:23
BTKi selection in R/R MCL: implications for sequencing non-covalent BTKis
Yucai Wang • 10 Sep 2026
The content of VJHemOnc is intended for healthcare professionals